Opportunities and challenges after biosecurity legislation - What we can and should do in environmental science and ecotechnology? [PDF]
Environ Sci Ecotechnol, 2021 Wang A.
europepmc +1 more source
LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro
Molecular Oncology, EarlyView.Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix +13 more
wiley +1 more source
Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition
Molecular Oncology, EarlyView.We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li +10 more
wiley +1 more source
Environmental Literacy and Accountability of Undergraduate Students of Medical Sciences
, 2020 Roghayeh Ershad Sarabi
openalex +1 more source
The Subjects’ Discursive Practices in Environmental Sciences at the Scientific Context of the University of Southwestern Bahia, Brazil [PDF]
, 2017 Silva Thiago Souza +1 more
openalex +1 more source
How spICP-TOF-MS and Related Techniques Are Beginning to Help Revolutionize Environmental Science. [PDF]
Environ Health (Wash)Hochella MF.
europepmc +1 more source
Ten principles for generating accessible and useable COVID-19 environmental science and a fit-for-purpose evidence base. [PDF]
Ecol Solut Evid, 2021 Kadykalo AN +3 more
europepmc +1 more source
Molecular Oncology, EarlyView.We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala +15 more
wiley +1 more source